Patent intelligence · AU
AU 2009324043
Novel composition for treatment of essential thrombocythemia
Novel composition for treatment of essential thrombocythemia
Patent details — AU 2009324043
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Jun 10, 2010
- Expiration
- Jun 5, 2030
- Applicant
- AOP ORPHAN PHARMACEUTICALS AG [AT]
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 60 A I, A61K 47/ 10 A I, A61K/31519
Quick answer
AU 2009324043 (Novel composition for treatment of essential thrombocythemia) is held by AOP ORPHAN PHARMACEUTICALS AG [AT]. Status: granted. Granted Jun 10, 2010. Expires Jun 5, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AOP ORPHAN PHARMACEUTICALS AG [AT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 60 A I, A61K 47/ 10 A I, A61K/31519, A61K/3160, A61K/4710
More from AOP ORPHAN PHARMACEUTICALS AG [AT]
Related pharmaceutical patents in our USPTO index.
-
WO 2025172541
NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES
granted -
WO 2025153663
LANDIOLOL COMPLEXÉ ENCAPSULÉ OU DISSOUS DANS UNE MATRICE LIPOPHILE
granted -
LT 3544598
CANNABINOIDS FOR PROPHYLACTIC TREATMENT OF INVOLUNTARY WEIGHT LOSS
granted -
EP 2988750
VERWENDUNG VON LANDIOLOLHYDROCHLORID BEI DER LANGZEITBEHANDLUNG VON TACHYARRHYTHMIEN
granted -
AU 2013258031
Parenteral esmolol formulation
granted -
AU 2008340179
Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
granted
Frequently asked questions
What is US patent 2009324043?
AU 2009324043 (Novel composition for treatment of essential thrombocythemia) is held by AOP ORPHAN PHARMACEUTICALS AG [AT]. Status: granted. Granted Jun 10, 2010. Expires Jun 5, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2009324043?
AOP ORPHAN PHARMACEUTICALS AG [AT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does AU 2009324043 expire?
Our index shows an expiration date of Jun 5, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.